All Posts

Introduction: Treatment Is No Longer Just About Controlling Blood Glucose For decades, the treatment of Type 1 Diabetes (T1D) has been relatively straightforward. If the body cannot produce insulin, we replace it. This approach works. It allows patients to manage the disease and maintain quality of life. But if you look one layer deeper, a fundamental limitation becomes clear: We have never truly changed the disease itself. The problem is not just a lack of insulin.It is that

Introduction: This Is Not a Sudden Disease Most people think of Type 1 Diabetes (T1D) as something that suddenly appears —one day you’re diagnosed, and from that point on, you depend on insulin. But from a biological perspective, T1D is not an abrupt event.It is a long, gradual process that can unfold over years, even decades. At the center of this process is the progressive breakdown of the Type 1 Diabetes autoimmune mechanism. The real question is not about blood glucose.It

Introduction: The Problem Was Never Just Blood Glucose If you’ve ever worked closely with Type 1 Diabetes (T1D), one realization comes quickly: “Dysregulated blood glucose” is just the final outcome. The real issue lies deeper — a systemic failure: The immune system begins to attack the body itself. This is why, despite over a century of insulin therapy, we’ve been able to manage T1D —but never truly solve it. 1. What is Type 1 Diabetes? (Type 1 Diabetes Overview) At its core

Executive Summary B cell protein factory represents a new paradigm for biologics delivery Through HSPC gene editing , B cells can be engineered to continuously secrete antibodies or therapeutic proteins The system is boostable, long-term, and capable of multi-protein output This signals a shift in cell therapy—from “killing cells” to “producing proteins” Companies like Be Biopharma and Immusoft are already moving in this direction Introduction: Are We Redefining Biologics?

Introduction: Are We Finally Beginning to “Understand” Biological Systems? In the past, the biotech industry rarely truly understood the systems it worked with. What we mostly did was: Run experiments Observe outcomes Adjust accordingly This approach works—but at its core, it is still trial-and-error driven science . The emergence of Digital Twin in Biotech represents a fundamental shift: We are starting to understand systems before running experiments. This is not just ab

Executive Summary Antibody drug conjugates (ADCs) have become one of the most important innovations in oncology and the broader biotech industry in recent years. Over the past decade, antibody drug conjugates have evolved from early-stage research tools into an integrated system spanning science, clinical development, manufacturing, and market strategy. Understanding ADCs solely from the perspective of molecular design or clinical efficacy is no longer sufficient. Antibody d

Introduction: Are We Missing the Most Important Piece? Over the past few years, mRNA therapeutics has rapidly expanded—from vaccines to cancer immunotherapy, gene editing, and protein replacement. But if you’ve actually worked in this space, you’ve probably had this intuition: Often, it’s not that your design isn’t good enough—it’s that delivery just doesn’t work. So we optimize: Codon usage Nucleoside modifications Cap and poly(A) tail LNP formulations All of these matter. B

Executive Summary Antibody–drug conjugates (ADCs) have rapidly evolved from an innovative therapeutic modality into one of the most strategically important areas in the biotech industry. In recent years, the ADC market has undergone significant changes: A surge in licensing deals and M&A activity Increasing investment from large pharmaceutical companies in ADC pipelines Growing focus among biotech startups on ADC platform technologies These trends indicate that: The ADC mark

Executive Summary Antibody–drug conjugates (ADCs) hold tremendous promise in both scientific innovation and clinical applications, but they also present significant challenges in manufacturing. Compared to traditional biologics or small-molecule drugs, ADC production involves: biologics (antibodies) highly potent small molecules (payloads) complex conjugation chemistry As a result, ADC manufacturing and CMC (Chemistry, Manufacturing, and Controls) often become critical bottl

Introduction: The Next Step of CAR-T Is Not “Better” — It’s “Simpler” Over the past decade, CAR-T therapy has proven that we can treat cancer with engineered immune cells. But the real bottleneck is never efficiency, but rather: Too high cost The manufacturing process is too slow Patients can't wait The essence of traditional CAR-T is actually "personalized cell manufacturing". Now, a more fundamental question has arisen: What if CAR-T didn't need to be manufactured at all? T

Executive Summary- ADC clinical development Antibody–drug conjugates (ADCs) have achieved major advances at the scientific and engineering levels, yet clinical success remains highly variable. Many ADCs: show strong performance in preclinical models demonstrate early responses in Phase I trials ultimately fail in Phase II or Phase III studies This indicates that the challenge is not solely molecular design, but rather: ADC clinical development strategy Successful ADC programs

In Vivo CAR-T Autoimmune Therapy: Reprogramming the Immune System In Situ Introduction CAR-T therapy has already transformed hematologic oncology. Yet its expansion into autoimmune disease has been limited by cost, manufacturing complexity, and scalability challenges. A new paradigm is emerging: in vivo CAR-T autoimmune therapy . Instead of extracting T cells, engineering them ex vivo, and reinfusing them weeks later, in vivo approaches program immune cells directly inside th

Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have become one of the most important therapeutic platforms in oncology drug development. Several ADCs have achieved major clinical success, particularly in breast cancer, hematologic malignancies, and emerging solid tumor indications. However, early generations of ADCs were still constrained by important limitations, including: reliance on a single payload mechanism dependence on a single tumor antigen

Introduction Following the success of COVID-19 vaccines, mRNA technology has rapidly emerged as one of the most important platforms in modern biotechnology . By enabling human cells to temporarily produce therapeutic proteins, mRNA therapeutics are being explored across a wide range of medical applications, including: Vaccines Cancer immunotherapy Protein replacement therapies Gene editing (CRISPR delivery) However, mRNA molecules are inherently fragile. Without protection,

Executive Summary Over the past decade, antibody–drug conjugates (ADCs) have emerged as one of the most promising platforms in oncology drug development. However, even clinically successful ADCs rarely maintain long-term tumor control when used as single agents. The reason is not simply insufficient drug potency. Tumors possess remarkable adaptive capacity and can gradually evade ADC-mediated cytotoxicity through mechanisms such as antigen downregulation, altered internaliza

Article Positioning This is Series (V) in the ADC deep-dive. In previous articles, we explored: The system-level design of antibody–drug conjugates Linker and conjugation engineering ADC target selection Clinical translation and platform strategy This article focuses on a critical reality: Even clinically successful ADCs eventually face ADC resistance . Understanding the mechanisms of ADC resistance is essential not only for biology, but for long-term product strategy. Execut

Introduction This is the fourth article in the ADC series. If previous articles discussed: The integrated system of antibody–drug conjugates (Series I) The evolution of ADC generations (Series II) Linker and conjugation as the engineering core (Series III) This article moves upstream to a more fundamental question: ADC target selection — which antigens are biologically suitable for ADC development? This article is written for readers without prior ADC experience who want to u

Introduction Why Has the LNP Field Long Lacked a “PDB-Level” Database? If you have worked directly on lipid nanoparticle (LNP) design for mRNA, siRNA, or CRISPR delivery, this situation may feel familiar: Extensive LNP screening has been performed across the field, yet much of the resulting data never truly accumulates into shared knowledge. The LNP field faces a structural challenge: large volumes of data exist, but they are highly fragmented and difficult to integrate. Diff

Introduction This is the third article in LuTra Studio’s ADC series, written for readers without a chemistry or ADC engineering background who want to understand why many antibody–drug conjugate programs fail despite having strong targets and potent payloads . This article focuses on ADC linker design and conjugation strategy —two elements often treated as technical details, but which frequently become structural failure points in clinical development and manufacturing scal

This is the second article in LuTra Studio’s ADC series, written for readers without prior ADC expertise who want to understand ADC evolution—specifically, why antibody–drug conjugates experienced widespread failures in the 2000s but emerged as one of the most important oncology platforms after 2020. Rather than starting with definitions, this article traces the historical failures, engineering corrections, and strategic shifts that shaped modern ADC development across differ